Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025(TM)

Stock Information for ADC Therapeutics SA

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ADC Therapeutics SA

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025(TM)
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.